AMRA-MEDICAL
10.4.2024 16:57:33 CEST | Business Wire | Press release
Researchers from AMRA Medical, a leading health informatics company providing body composition analysis through magnetic resonance imaging (MRI), together with Eli Lilly, and researchers from Nantes Université, University Hospitals Cleveland, and Linköping University used visceral-, subcutaneous-, and liver fat z-scores derived from MRI to investigate changes in fat distribution patterns in patients with type 2 diabetes (T2D) participating in SURPASS-3 MRI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410636011/en/
AMRA Medical's Personalized Fat Z-scores (Photo: Business Wire)
Absolute (or percent) change in body weight and/or BMI are still typical endpoints in clinical trials evaluating treatments for obesity and related disorders. However, the research team’s recent findings from the SURPASS-3 MRI study suggest that pharmacological treatments for T2D may alter the fat distribution pattern in various ways - independent of changes in body weight. For this reason, fat distribution profiling through personalized z-score assessment would represent an attractive and modifiable endpoint for future therapeutic efficacy trials in obesity and related disorders.
The personalized fat z-scores were introduced through research published in 2023 linking fat distribution patterns, as described by the z-scores, to specific cardiometabolic disease risk profiles in the general population. This was quickly followed by Surgery for Obesity and Related Diseases (SOARD) publishing results on risk-stratification of obesity class I & II by the fat z-scores in the American Society for Metabolic and Bariatric Surgery (ASMBS) guidelines/statements journal section of SOARD. (Read more about z-score use in risk-stratification here).
The current exploratory analysis of data from Lilly’s SURPASS-3 MRI study, described changes in the fat z-scores in people with T2D following treatment with once-weekly tirzepatide (5, 10 or 15 mg dose) or once-daily basal insulin degludec for 52 weeks. The results showed that treatment with tirzepatide was associated with a significant reduction in visceral fat z-score (-0.18 SD) and liver fat z-score (-0.54 SD), while the subcutaneous fat z-score increased from an initially negative value (+0.11 SD) - suggesting a therapeutically-induced shift towards a better-balanced body fat distribution with prominent visceral and liver fat loss.
During follow-up of interventions that induce weight reduction, it has been difficult to determine whether a concurrent reduction of, e.g., visceral fat was in line with the amount of weight lost, or if there was larger reduction than expected. The significant reduction of visceral fat and liver fat z-scores observed with tirzepatide in SURPASS-3 MRI indicates a potential targeted effect beyond that expected by the magnitude of weight reduction.
Read the full publication titled ‘Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes’ here.
About AMRA Medical
AMRA Medical is a health informatics company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition analysis, delivering multiple fat and muscle biomarkers with unrivalled accuracy and precision – all from a rapid whole-body MRI scan. AMRA offers clinical services and research services to support transformative care and vital decision-making, from clinical research to clinical care.
Learn more about AMRA Medical’s MRI-based solutions at https://amramedical.com/solutions or connect with our team of experts for a detailed discussion at info@amramedical.com.
Follow AMRA on LinkedIn for the latest updates in body composition and precision medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410636011/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom